Myeloma cell adhesion to BMSCs supports cell survival, proliferation, and cell adhesion-mediated drug resistance (CAM-DR) via signaling pathway activation, including the NF-kB (nuclear factor-kB), JAK/Stat3 (Janus kinase/signal transducer and activator of transcription-3), and MEK/MAPK (mitogen activated protein [MAP] kinase kinase/MAP kinase) pathways [36], [37]. Here, NFKB1 is linked to plasma cell myeloma.